广济药业
(000952)
| 流通市值：22.84亿 | | | 总市值：23.02亿 |
| 流通股本：3.44亿 | | | 总股本：3.47亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 284,356,305.48 | 148,487,959.52 | 638,801,583.21 | 462,193,617.06 |
| 营业收入 | 284,356,305.48 | 148,487,959.52 | 638,801,583.21 | 462,193,617.06 |
| 二、营业总成本 | 367,756,063.23 | 190,322,337.88 | 910,522,662.26 | 628,443,566.8 |
| 营业成本 | 197,976,934.47 | 105,498,174.52 | 519,103,181.97 | 355,863,712.34 |
| 税金及附加 | 8,620,067.33 | 4,121,561.29 | 15,582,766.8 | 10,074,266.42 |
| 销售费用 | 15,611,717.52 | 9,722,850.34 | 48,706,675.33 | 28,388,827.8 |
| 管理费用 | 95,864,154.22 | 50,730,521.8 | 214,326,929.58 | 150,503,843.52 |
| 研发费用 | 24,883,031.62 | 10,910,609.64 | 56,816,615.67 | 44,704,949.95 |
| 财务费用 | 24,800,158.07 | 9,338,620.29 | 55,986,492.91 | 38,907,966.77 |
| 其中:利息费用 | 26,434,422.46 | 9,948,401.26 | 61,976,137.73 | 44,081,543.01 |
| 其中:利息收入 | 518,271.6 | 330,447.69 | 2,062,005.04 | 1,650,786.48 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | - | - | -27,920,916.28 | -3,643,763.21 |
| 资产处置收益 | - | - | -2,402,290.22 | - |
| 资产减值损失(新) | -2,966,566.77 | 358,511.67 | -34,611,117 | -14,763,673.28 |
| 信用减值损失(新) | 908,443.79 | 164,962.35 | 2,800,576.32 | 392,004.92 |
| 其他收益 | 3,954,609.43 | 1,327,999.22 | 15,958,866.29 | 13,747,602.28 |
| 四、营业利润 | -81,503,271.3 | -39,982,905.12 | -317,895,959.94 | -170,517,779.03 |
| 加:营业外收入 | 8,307.49 | 401.1 | 1,646,025.36 | 1,106,544.29 |
| 减:营业外支出 | 254,457.8 | 203,998.99 | 4,043,968.4 | 1,588,135.66 |
| 五、利润总额 | -81,749,421.61 | -40,186,503.01 | -320,293,902.98 | -170,999,370.4 |
| 减:所得税费用 | 554,342.67 | -6,811.91 | -5,159,841.19 | 1,457,811.36 |
| 六、净利润 | -82,303,764.28 | -40,179,691.1 | -315,134,061.79 | -172,457,181.76 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -82,303,764.28 | -40,179,691.1 | -315,134,061.79 | -172,457,181.76 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -75,515,062.44 | -36,266,158.34 | -295,291,149.72 | -158,575,596.68 |
| 少数股东损益 | -6,788,701.84 | -3,913,532.76 | -19,842,912.07 | -13,881,585.08 |
| 扣除非经常损益后的净利润 | -78,410,879.83 | -37,251,540.81 | -303,289,019.5 | -171,650,698.13 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.22 | -0.1 | -0.84 | -0.45 |
| (二)稀释每股收益 | -0.21 | -0.1 | -0.82 | -0.45 |
| 八、其他综合收益 | 268.18 | 82.74 | -7,235.21 | -1,591.39 |
| 归属于母公司股东的其他综合收益 | 268.18 | 82.74 | -7,235.21 | -1,591.39 |
| 九、综合收益总额 | -82,303,496.1 | -40,179,608.36 | -315,141,297 | -172,458,773.15 |
| 归属于母公司股东的综合收益总额 | -75,514,794.26 | -36,266,075.6 | -295,298,384.93 | -158,577,188.07 |
| 归属于少数股东的综合收益总额 | -6,788,701.84 | -3,913,532.76 | -19,842,912.07 | -13,881,585.08 |
| 公告日期 | 2025-08-29 | 2025-04-28 | 2025-04-28 | 2024-10-31 |
| 审计意见(境内) | | | 带强调事项段的无保留意见 | |